Zenas BioPharma (NASDAQ:ZBIO) Director Fairmount Funds Management Llc Acquires 150,000 Shares

Zenas BioPharma, Inc. (NASDAQ:ZBIO) Director Fairmount Funds Management Llc acquired 150,000 shares of the stock in a transaction that occurred on Tuesday, March 31st. The stock was purchased at an average price of $20.00 per share, for a total transaction of $3,000,000.00. Following the completion of the transaction, the director owned 2,359,025 shares in the company, valued at $47,180,500. The trade was a 6.79% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this link.

Zenas BioPharma Stock Up 5.4%

Shares of Zenas BioPharma stock opened at $21.46 on Friday. Zenas BioPharma, Inc. has a one year low of $6.11 and a one year high of $44.60. The company has a market cap of $1.23 billion, a P/E ratio of -2.75 and a beta of -0.54. The company has a debt-to-equity ratio of 0.32, a quick ratio of 5.61 and a current ratio of 5.61. The firm has a fifty day moving average of $23.15 and a two-hundred day moving average of $27.22.

Zenas BioPharma (NASDAQ:ZBIO) last issued its earnings results on Monday, March 16th. The company reported ($4.54) earnings per share for the quarter, missing the consensus estimate of ($1.22) by ($3.32).

Hedge Funds Weigh In On Zenas BioPharma

Several hedge funds have recently bought and sold shares of ZBIO. SR One Capital Management LP boosted its position in Zenas BioPharma by 2.6% during the fourth quarter. SR One Capital Management LP now owns 5,037,854 shares of the company’s stock worth $182,924,000 after purchasing an additional 126,315 shares in the last quarter. NEA Management Company LLC increased its position in shares of Zenas BioPharma by 28.9% in the fourth quarter. NEA Management Company LLC now owns 3,523,219 shares of the company’s stock valued at $127,928,000 after buying an additional 789,500 shares in the last quarter. Federated Hermes Inc. raised its stake in shares of Zenas BioPharma by 45.9% during the 4th quarter. Federated Hermes Inc. now owns 2,715,578 shares of the company’s stock worth $98,603,000 after buying an additional 853,740 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of Zenas BioPharma by 25.0% during the 4th quarter. Vanguard Group Inc. now owns 1,453,065 shares of the company’s stock worth $52,761,000 after buying an additional 290,307 shares during the last quarter. Finally, Polar Capital Holdings Plc purchased a new stake in shares of Zenas BioPharma in the 4th quarter worth about $38,402,000.

Wall Street Analyst Weigh In

ZBIO has been the topic of several recent analyst reports. Guggenheim boosted their target price on Zenas BioPharma from $45.00 to $55.00 and gave the stock a “buy” rating in a research report on Monday, March 16th. HC Wainwright restated a “buy” rating and issued a $44.00 price target on shares of Zenas BioPharma in a research note on Tuesday, March 17th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Zenas BioPharma in a report on Friday, March 27th. Wedbush reiterated an “outperform” rating and issued a $45.00 price objective on shares of Zenas BioPharma in a research report on Monday, December 22nd. Finally, Morgan Stanley raised their target price on Zenas BioPharma from $19.00 to $21.00 and gave the company an “equal weight” rating in a report on Tuesday, March 17th. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $44.14.

About Zenas BioPharma

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.